Department of Pharmaceutics, Institute of Pharmacology and Toxicology of Academy of Military Medical Sciences, Beijing, China.
Drug Deliv. 2021 Dec;28(1):19-36. doi: 10.1080/10717544.2020.1856224.
In recent years, nanocrystal technology has been extensively investigated. Due to the submicron particle size and unique physicochemical properties of nanocrystals, they overcome the problems of low drug solubility and poor bioavailability. Although the structures of nanocrystals are simple, the further development of these materials is hindered by their stability. Drug nanocrystals with particle sizes of 1∼1000 nm usually require the addition of stabilizers such as polymers or surfactants to enhance their stability. The stability of nanocrystal suspensions and the redispersibility of solid nanocrystal drugs are the key factors for the large-scale production of nanocrystal preparations. In this paper, the factors that affect the stability of drug nanocrystal preparations are discussed, and related methods for solving the stability problem are put forward.
近年来,纳米晶体技术得到了广泛的研究。由于纳米晶体的亚微米粒径和独特的物理化学性质,它们克服了药物溶解度低和生物利用度差的问题。尽管纳米晶体的结构简单,但由于其稳定性问题,这些材料的进一步发展受到了阻碍。粒径为 1∼1000nm 的药物纳米晶体通常需要添加聚合物或表面活性剂等稳定剂来提高其稳定性。纳米晶体混悬液的稳定性和固体纳米晶体药物的再分散性是纳米晶体制剂大规模生产的关键因素。本文讨论了影响药物纳米晶体制剂稳定性的因素,并提出了相关的稳定性问题解决方法。